why choose us

🌐 Go to WebHealthNetwork.com
Go to Consumers Chat
300×250 Ad Slot

Research Article: Urinary quality of life in patients treated with prostate SBRT with intra-prostatic boost

Date Published: 2025-09-30

Abstract:
SBRT is a standard of care treatment for localized prostate cancer. Whole gland dose escalation remains controversial. Concomitant intraprostatic boost (IPB) may offer an acceptable compromise for dose escalation. In this series, we report changes in International Prostate Symptom Scores (IPSS) over a 12-month period following SBRT with IPB in patients treated in a large academic institution. Seventy-four patients treated from October 2018 to March 2022 with robotic stereotactic body radiotherapy completed IPSS questionnaires. IPSS were evaluated for patients at three timepoints: pre-treatment, post-treatment (defined as 3 months after SBRT completion), and at follow-up (defined as within 12 months after SBRT completion). The patients were stratified into two cohorts: patients who experienced minimally important difference (MID) in their post-treatment IPSS and those who did not. Urethral and bladder doses were retrospectively extracted from the treatment planning software and compared between the two cohorts using Wilcoxon rank sum test. Of the 74 patients, 46 (62%) experienced MID in scores (cohort A), while 28 (38%) did not (cohort B). Patient characteristics in the two cohorts such as risk stratification and initial PSA were well-balanced. Median IPSS for cohort A were 5 (range: 0–21) pre-treatment, 12 (range: 3–28) post-treatment, and 8 (range: 1–32) at 12 months. For cohort B, the scores were 9.5 (range: 0–29), 7 (range: 1–19), and 8.5 (range: 0-32), respectively. In addition, there was a statistically significant difference in D0.03cc to the bladder in cohort A compared to cohort B (41.9 Gy vs 40.2 Gy; p < 0.001). IPB is well tolerated with acceptable change in urinary quality of life metrics as measured by IPSS. Max dose to the bladder remains the only significant difference in patients who experienced MID in their urinary quality of life.

Introduction:
Stereotactic body radiotherapy (SBRT) has become a standard treatment for localized prostate cancer, offering favorable disease control with a hypofractionated schedule ( 1 ). This approach significantly reduces treatment duration while maintaining outcomes comparable to conventional fractionation regimens. However, SBRT necessitates precise dosimetric planning to limit dose exposure to adjacent organs at risk (OARs), particularly the bladder and urethra. Excess dose to these structures has been linked to acute…

Read more

300×250 Ad Slot